Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $480 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates and platform technologies.

CEPI is also funding seven programmes which aim to rapidly advance the development of vaccine candidates against the COVID-19 virus.

Filter by:

PRODUCT DEVELOPERS
  • All
  • Colorado State University
  • CureVac
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • Institut Pasteur, Themis Bioscience, University of Pittsburgh
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Moderna, Inc.
  • Novavax, Inc.
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Public Health Vaccines
  • The University of Hong Kong
  • Themis Bioscience
  • University of Oxford
  • University of Queensland
  • University of Tokyo
  • Valneva SE
  • Wageningen Bioveterinary Research
DISEASE
  • All
  • Chikungunya
  • COVID-19
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rift Valley Fever
VACCINE TYPE
  • All
  • ChAdOx1
  • Live attenuated vaccine
  • Measles vector
  • Nucleic acid
  • Recombinant protein
  • Recombinant protein nanoparticle technology
  • Recombinant viral vector
PHASE
  • All
  • Phase 1
  • Phase 2
  • Phase 3
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result

©2020 CEPI. All rights reserved

This website uses cookies to improve functionality and performance. If you continue browsing the site, you consent to the use of cookies on this website. For details, see our Cookie Notice.